Response to: 'Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'' by Pethoe-Schramm et al
- PMID: 32737110
- DOI: 10.1136/annrheumdis-2020-218403
Response to: 'Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'' by Pethoe-Schramm et al
Keywords: antirheumatic agents; arthritis, rheumatoid; inflammation.
Conflict of interest statement
Competing interests: Dr Aletaha reports grants and personal fees from Roche, outside the submitted work. Dr Smolen received grants to his institution from AbbVie, AstraZeneca, Janssen, Lilly, Merck Sharp & Dohme, Pfizer and Roche and provided expert advice for or had symposia speaking engagements with AbbVie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Gilead, Glaxo, ILTOO Pharma, Janssen, Lilly, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi and UCB.
Comment on
-
Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab.Ann Rheum Dis. 2020 Jul;79(7):874-882. doi: 10.1136/annrheumdis-2019-215987. Epub 2020 May 5. Ann Rheum Dis. 2020. PMID: 32371387
-
Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'.Ann Rheum Dis. 2022 Aug;81(8):e136. doi: 10.1136/annrheumdis-2020-218365. Epub 2020 Jul 31. Ann Rheum Dis. 2022. PMID: 32737114 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
